Related Experiment Video
Updated: Mar 25, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Yttrium-90 Radioembolization for Hepatocellular Carcinoma
Ryan M Hickey1, Robert J Lewandowski1, Riad Salem1
1Department of Radiology, Division of Vascular & Interventional Radiology, Northwestern University, Feinberg School of Medicine, Chicago, IL.
Abstract:
(90)Y radioembolization refers to the selective, transcatheter, and intra-arterial injection of micrometer-sized particles loaded with the radioisotope yttrium-90 for the treatment of primary and metastatic hepatic malignancies. In the treatment of intermediate- and advanced-stage hepatocellular carcinoma, (90)Y radioembolization provides favorable outcomes with minimal side effects, offering an alternative treatment option to other transarterial therapies, such as bland embolization and chemoembolization. This review provides an overview of the use of (90)Y radioembolization in the treatment of hepatocellular carcinoma, including patient selection criteria, dosimetry, and clinical outcomes.
More Related Videos
05:31Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013